

**Table S1.** The genotype distribution in 436 NSCLC patients.

SNP	Genotype	n (%)	Allele	Function class <sup>a</sup>	Regulome DB rank <sup>b</sup>	MAF
rs2227983	GG	231 (53)	Arg521Lys G>A	NS; splicing (ESE/ESS)	5	0.26
	GA	171 (39)				
	AA	25 (6)				
	Missing	9 (2)				
rs712830	CC	289 (66)	-191 C>A	promoter; TFBS; splicing (ESE/ESS)	4	0.19
	CA	126 (29)				
	AA	21 (5)				
rs712829	GG	211 (48)	-216 G>T	promoter; TFBS; splicing (ESE/ESS)	2a	0.30
	GT	191 (44)				
	TT	34 (8)				

NSCLC, non–small cell lung cancer; SNP, single nucleotide polymorphism; MAF, minor allele frequency; NS, nonsynonymous; TFBS, transcription factor binding site; ESE/ESS, exonic splicing enhancer/exonic splicing silencer; <sup>a</sup> <https://www.regulomedb.org>; <sup>b</sup> <https://snpinfo.nih.gov/snpinfo/snpfunc.html>

**Figure S1.** Linkage disequilibrium (LD) analysis and haplotype block structure for three *EGFR* polymorphisms examined in the study—rs712830 (EGFR -216), rs712829 (EGFR -191) and rs2227983 (EGFR 521). The numbers represent the pairwise  $D'$  values expressed as percentages. The darkness of the cells indicates the strength of LD.

